Gastrointestinal Cancer
FDA Authorizes Marketing for AI Colon Cancer Detection Device
April 12, 2021
Article
The FDA has authorized the marketing of the first device that utilizes artificial intelligence based on machine learning to help clinicians detect lesions like polyps or suspected tumors in the colon in real time during a colonoscopy.
FDA Approves Additional Cetuximab Dose for KRAS Wild-Type, EGFR-Expressing CRC, Head and Neck Cancer
April 07, 2021
Article
The FDA has approved a new biweekly dosing regimen of 500 mg/m2 as a 120-minute intravenous infusion for cetuximab (Erbitux) for patients with KRAS wild-type, EGFR-expressing colorectal cancer or squamous cell carcinoma of the head and neck.
Research Will Reveal Optimal Drug Sequencing in Pancreatic Cancer
April 05, 2021
Article
Optimizing first- and second-line therapy, understanding the role of maintenance therapy for patients with BRCA-positive disease, and developing improved therapeutic options for elderly patients has become a priority for research in metastatic pancreatic cancer.
Immunotherapy Enters Gastroesophageal and Gastric Cancers
March 25, 2021
Article
Namrata (Neena) Vijayvergia, MD, discusses the emerging role of immunotherapy in resectable and metastatic esophageal and gastric cancers, as well as key nuances that could complicate these agents’ utility in clinical practice.
New Treatment Methods Launch a Shift in CRC Treatment
March 13, 2021
Article
Tony Philip, MD, provides insight into the utility of ctDNA in the early-stage setting, trials that could determine its role in clinical practice, and detailed the shift toward nonoperative and less-intensive interventions in the early-stage and advanced settings, respectively.
Nivolumab/Chemo Granted Priority Review for Frontline Metastatic Gastric, GEJ, and Esophageal Cancer
January 20, 2021
Article
The FDA has granted a priority review to a supplemental biologics license application for nivolumab (Opdivo) in combination with a fluoropyrimidine- and platinum-containing chemotherapy for use in patients with advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, or esophageal adenocarcinoma.
Step Count May Boost QOL in Patients Receiving SM-88
January 18, 2021
Article
Mean daily step count during the first 2 weeks of treatment with SM-88 (racemetyrosine) was found to correlate with overall self-reported quality of life (QoL) in patients with metastatic pancreatic cancer.
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for HER2+ Gastric Adenocarcinomas
January 16, 2021
Article
The FDA approved fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of patients with locally advanced or metastatic HER2-postive gastric or gastroesophageal (GEJ) adenocarcinoma who previously received a trastuzumab-based regimen.
Team Up, Be Aggressive: Improving Outcomes for Metastatic Colon Cancer
January 14, 2021
Article
The management of patients with colorectal liver metastases is complicated and requires careful assessment from a multidisciplinary tumor board—especially in light of recent advances made with chemotherapy, according to Michael J. Cavnar, MD.
Opioid Use May Increase Pancreatic Cancer Risk
January 08, 2021
Article
Recent research found that there may be a correlation between opioid use and pancreatic cancer risk.